Meda Acquires Roche Products

Meda has reached an agreement with Roche to acquire four of its pharmaceutical products, strengthening its key therapy areas: cardiology, CNS and pain/inflammation. Meda acquired worldwide rights to the products, with the major markets including Germany, Spain, Switzerland, the U.S. and France. The purchase price is approximately $180 million, equivalent to about two times annual sales.
   
The acquired products are: Marcoumar, an anticoagulant; Torem, an antihypertensive; Tilcotil, a NSAID drug for the treatment of painful inflammatory and degenerative disorders such as rheumatoid arthritis and osteoarthritis; and Aurorix, a MAO-A inhibitor and antidepressant. The acquisition is dependent on antitrust approval.
  
“I’m glad that we could reach this deal with Roche. The products strengthen our marketing affiliates’ position in key therapy areas. Therefore, good market synergies are expected,” said Anders Lonner, chief executive officer of Meda.